ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > WTF is going on?

<< Previous

Bullboard Posts

Next >>

Comment by M101on Jul 17, 2023 11:10am

156 Views

Post# 35544138

RE:RE:WTF is going on?

G1945V wrote:
BottomBroker wrote: Is this due to the presentation? Or impending news that hasn't been annouced yet?

We're up 160% and climbing.

They should have dropped TSX when they went NASDAQ, right off the bat.

G1945V

We want the truth? We can't handle the truth!

Let's assume that what ultimately happened was the reason they did not do that. So then it follows that there was some new reason for doing it last week. Did they want this volatility or was it simply the cash situation and how best to leverage any AAIC/ABOS bump?

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload